Total trials
45
Active
2
Phase 3
0
Total enrollment
3,450
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| zelicapavir | — | — | — | — | 2 | ||
| EDP-978 | — | — | — | — | — | 1 |
Next readouts
- 2026-11
- 2026-12
Top conditions
- RSV Infection13
- NASH - Nonalcoholic Steatohepatitis4
- Respiratory Syncytial Virus (RSV)3
- COVID-193
- Hepatitis C2
- Non-Alcoholic Steatohepatitis2
- Chronic HBV Infection2
- NASH2
Frequently asked questions about Enanta Pharmaceuticals, Inc
- How many clinical trials does Enanta Pharmaceuticals, Inc have on ClinicalTrials.gov?
- Enanta Pharmaceuticals, Inc is listed as the lead sponsor on 45 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Enanta Pharmaceuticals, Inc's trials are in Phase 3?
- 0 of Enanta Pharmaceuticals, Inc's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Enanta Pharmaceuticals, Inc focus on?
- Enanta Pharmaceuticals, Inc's most-studied conditions on ClinicalTrials.gov are RSV Infection, NASH - Nonalcoholic Steatohepatitis, Respiratory Syncytial Virus (RSV), COVID-19, Hepatitis C.
- When are Enanta Pharmaceuticals, Inc's next clinical trial readouts?
- Enanta Pharmaceuticals, Inc has 2 upcoming primary-completion readouts tracked here; the soonest is “A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults”, expected around 2026-11.